Preston Thomas J, Olshove Vincent F, Chase Margaret
The Department of Cardiovascular Perfusion, The Heart Center at Nationwide Children's Hospital, Columbus, Ohio 43205, USA.
J Extra Corpor Technol. 2012 Mar;44(1):39-42.
The successful use of prolonged extracorporeal life support with a heart-lung machine was first performed in 1972, as described by Hill et al., on a young man with post-traumatic respiratory failure. The first successful use of extracorporeal membrane oxygenation (ECMO) was 1976 by Bartlett et al. Since this time, the use of ECMO for neonatal and pediatric pulmonary support has become a standard of care in many children's hospitals. The use of ECMO, being a very invasive procedure, is not without risk. In our experience, most patients require multiple transfusions of the different blood components (packed red blood cells, plasma, platelets, and cryoprecipitate). Exposure to one or more blood products often occurs with connection to the ECMO circuit, as the circuit is generally primed with blood products or whole blood. Jehovah's Witnesses (JWs) are known best in the medical community for their refusal of blood products, even at the risk of death, which presents challenges for health care providers. This belief stems from the biblical passages that have been quoted as forbidding transfusion: Genesis 9:3-4, Leviticus 17:13-14, and Acts 15:19-21. This refusal of blood poses even greater challenges when treating the pediatric JW population. When a blood product is deemed medically necessary for the JW patient, the healthcare provider must either seek legal intervention, or support the patient's/family's wishes and associated outcome. This ethical dilemma may be further complicated in the setting of therapies, which may pose additional risks and potentially less clear benefit such as with ECMO. Bloodless cardiac surgery with cardiopulmonary bypass has been reported in the JW population in adults and pediatrics, including neonates. After a thorough search of the literature, no published report of a JW patient being supported on ECMO without blood or blood component utilization was identified. This case report will present our experience with multiple day, bloodless ECMO support of a 17-year-old male patient of the JW faith.
1972年,希尔等人首次成功地使用心肺机进行长时间体外生命支持,对象是一名患有创伤后呼吸衰竭的年轻男子。1976年,巴特利特等人首次成功使用体外膜肺氧合(ECMO)。从那时起,ECMO在新生儿和儿科肺部支持中的应用已成为许多儿童医院的护理标准。ECMO作为一种侵入性很强的操作,并非没有风险。根据我们的经验,大多数患者需要多次输注不同的血液成分(浓缩红细胞、血浆、血小板和冷沉淀)。由于ECMO回路通常用血液制品或全血预充,连接到ECMO回路时经常会接触到一种或多种血液制品。耶和华见证人(JW)在医学界最为人所知的是他们拒绝使用血液制品,即使冒着死亡风险,这给医疗服务提供者带来了挑战。这种信仰源于被引用为禁止输血的圣经经文:《创世纪》9:3 - 4、《利未记》17:13 - 14和《使徒行传》15:19 - 21。在治疗儿科JW人群时,这种对血液的拒绝带来了更大的挑战。当血液制品被认为对JW患者的医疗是必要的时,医疗服务提供者必须要么寻求法律干预,要么支持患者/家属的意愿及相关结果。在ECMO等可能带来额外风险且潜在益处不太明确的治疗情况下,这种伦理困境可能会更加复杂。在成人、儿科包括新生儿的JW人群中,已经报道了无血体外循环心脏手术。在对文献进行全面检索后,未发现有关于JW患者在不使用血液或血液成分的情况下接受ECMO支持的已发表报告。本病例报告将介绍我们对一名17岁JW信仰男性患者进行多日无血ECMO支持的经验。